Seagen and Lava Therapeutics Ink Licensing Deal Worth Up to $700 Million
Seagen and Lava Therapeutics have inked a licensing deal that would give Seagen access to Lava’s proprietary technology that targets epidermal growth factor receptor (EGFR)-expressing solid tumors.
The company’s LAVA-1223 Gammabody technology directs gamma delta T cells to kill target cells and trigger immune activation while minimizing the impact on normal antigen-expressing tissue, with the aim of providing durable immune responses and the possibility of enhancing patient survival.
Seagen will pay Lava $50 million upfront, plus up to approximately $650 million in potential development, regulatory and commercial milestones. The agreement also gives Seagen the opportunity to exclusively negotiate rights to apply Lava's proprietary Gammabody platform on up to two additional tumor targets.